Latest Period
Q2 2026
CUSIP: 90240B106
Latest Period
Q2 2026
Institutions Reporting
167
Shares (Excl. Options)
69,338,885
Price
$31.94
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 167 institutions filings for Q2 2026.
Security key
90240B106
Latest holder period
Q2 2026
13F holders
167
13D/G owners
14
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP 90240B106:
13D/G owners
Large-stake holder rows connected to Schedule 13D/G evidence.
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20% | -6.2% | $369,229,756 | +$48,704,151 | 14,130,492 | +15% | RA Capital Management, L.P. | 15 Sep 2026 |
| FMR LLC | 14% | +373% | $296,738,016 | +$231,353,566 | 7,747,648 | +354% | FMR LLC | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 7.2% | +36% | $148,931,747 | +$39,592,966 | 3,890,589 | +36% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| Farallon Capital Partners, L.P. | 6.6% | +17% | $137,073,713 | +$22,814,880 | 3,580,818 | +20% | Dapice Joshua J. | 31 Mar 2026 |
| NEXTECH VI ONCOLOGY SCSP | 6% | $115,740,263 | 3,553,585 | Nextech VI Oncology SCSp | 30 Jun 2026 | |||
| Paradigm Biocapital Advisors LP | 5.8% | $90,761,327 | 3,473,453 | Paradigm BioCapital Advisors LP | 10 Sep 2026 | |||
| BlackRock, Inc. | 5% | $95,060,722 | 2,976,228 | BlackRock, Inc. | 30 Jun 2026 | |||
| Harris Todd | 4.8% | -6% | $111,522,732 | +$3,788,304 | 2,913,342 | +3.5% | Todd Harris | 31 Mar 2026 |
| TCG Crossover GP I, LLC | 5.7% | $29,792,499 | 2,898,103 | TCG Crossover GP I, LLC | 27 Feb 2025 | |||
| Commodore Capital LP | 4.2% | -35% | $94,743,000 | -$34,452,000 | 2,475,000 | -27% | Commodore Capital LP | 31 Mar 2026 |
| Vestal Point Capital, LP | 4.5% | -18% | $33,925,750 | -$6,363,058 | 2,425,000 | -16% | Vestal Point Capital, LP | 30 Sep 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 4% | -48% | $64,574,633 | -$55,131,655 | 2,127,665 | -46% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Canaan XI L.P. | 1.4% | -68% | $28,725,000 | -$83,511,005 | 750,000 | -74% | Canaan XI L.P. | 31 Mar 2026 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 0% | $195,420 | 6,000 | Farallon Capital Management, L.L.C. | 30 Jun 2026 |
As of 30 Jun 2026, 167 institutional investors reported holding 69,338,885 shares of Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (TYRA). This represents 98% of the company’s total 71,007,497 outstanding shares.
13F concentration
Largest 13F positions for this security by reported shares and value.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 17% | 12,198,625 | 0% | 3.4% | $389,624,083 |
| FMR LLC | 13% | 8,920,513 | +15% | 0.01% | $284,921,184 |
| Jupiter Topco LLC | 6.1% | 4,352,448 | 0% | 0.06% | $139,161,460 |
| Alta Partners Management Company, L.P. | 5.4% | 3,823,425 | 0% | 96% | $122,120,195 |
| Nextech Invest Ltd. | 5% | 3,553,585 | -12% | 5.4% | $113,501,505 |
| TCG Crossover Management, LLC | 4.6% | 3,248,980 | 0% | 2.5% | $103,772,421 |
| BlackRock, Inc. | 4.3% | 3,031,972 | +37% | 0% | $96,841,186 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.9% | 2,782,567 | +182% | 0.01% | $88,876,000 |
| STATE STREET CORP | 3% | 2,140,368 | +76% | 0% | $68,363,354 |
| Commodore Capital LP | 2.6% | 1,875,000 | -24% | 3.6% | $59,887,500 |
| Paradigm Biocapital Advisors LP | 2.6% | 1,828,607 | -11% | 1.1% | $58,405,708 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1% | 1,508,447 | +34% | 0% | $48,179,797 |
| BVF INC/IL | 2.1% | 1,476,196 | -25% | 1.2% | $47,149,700 |
| 5AM Venture Management, LLC | 1.4% | 1,029,298 | 0% | 11% | $32,875,778 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.4% | 1,017,000 | +85% | 0.34% | $32,482,980 |
| Hood River Capital Management LLC | 1.4% | 1,016,775 | 0.24% | $32,475,794 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 970,734 | +47% | 0% | $31,010,333 |
| Caligan Partners LP | 1.1% | 806,986 | -37% | 1.2% | $25,775,133 |
| Canaan Partners XI LLC | 1.1% | 750,000 | 0% | 19% | $23,955,000 |
| Siren, L.L.C. | 1% | 725,000 | 0.47% | $23,156,500 | |
| Sio Capital Management, LLC | 0.98% | 695,315 | +15% | 3.8% | $22,208,361 |
| STEMPOINT CAPITAL LP | 0.89% | 632,754 | +228% | 3.5% | $20,210,163 |
| MARSHALL WACE, LLP | 0.82% | 583,133 | +195% | 0.02% | $18,625,268 |
| GOLDMAN SACHS GROUP INC | 0.65% | 463,477 | -16% | 0% | $14,803,455 |
| JENNISON ASSOCIATES LLC | 0.64% | 450,964 | -29% | 0.01% | $14,403,791 |
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 69,338,885 | $2,215,214,954 | +$57,816,117 | $31.94 | 167 |
| 2026 Q1 | 65,938,350 | $2,524,644,934 | +$382,078,810 | $38.30 | 163 |
| 2025 Q4 | 56,830,609 | $1,493,991,866 | +$12,760,989 | $26.29 | 133 |
| 2025 Q3 | 55,638,635 | $778,399,313 | -$9,877,671 | $13.99 | 115 |
| 2025 Q2 | 56,588,644 | $541,513,140 | +$28,813,504 | $9.57 | 120 |
| 2025 Q1 | 53,573,458 | $499,522,930 | +$34,676,031 | $9.30 | 116 |
| 2024 Q4 | 48,613,623 | $675,760,666 | -$145,254,713 | $13.90 | 112 |
| 2024 Q3 | 47,054,295 | $1,105,994,170 | +$8,152,750 | $23.51 | 94 |
| 2024 Q2 | 46,814,701 | $748,570,507 | -$1,810,347 | $15.99 | 76 |
| 2024 Q1 | 46,852,011 | $768,372,899 | +$182,484,246 | $16.40 | 75 |
| 2023 Q4 | 35,756,693 | $495,188,385 | -$9,797,725 | $13.85 | 62 |
| 2023 Q3 | 36,462,633 | $502,118,395 | +$3,284,853 | $13.77 | 59 |
| 2023 Q2 | 36,210,809 | $616,671,033 | +$8,028,494 | $17.03 | 59 |
| 2023 Q1 | 35,654,296 | $572,964,060 | +$8,455,742 | $16.07 | 50 |
| 2022 Q4 | 35,239,863 | $267,821,738 | -$5,207,345 | $7.60 | 45 |
| 2022 Q3 | 35,692,923 | $313,754,295 | -$403,922 | $8.79 | 43 |
| 2022 Q2 | 35,744,229 | $255,572,000 | -$3,322,156 | $7.15 | 44 |
| 2022 Q1 | 36,133,976 | $386,624,000 | -$8,627,515 | $10.70 | 46 |
| 2021 Q4 | 35,174,367 | $494,157,000 | +$13,654,547 | $14.07 | 45 |
| 2021 Q3 | 26,080,552 | $456,755,000 | +$456,755,000 | $17.59 | 25 |